TC BioPharm's CEO to Share Insights on Cancer at European Forum

TC BioPharm CEO Bryan Kobel to Participate in Cancer Progress Panel

TC BioPharm (Holdings) PLC, listed under NASDAQ: TCBP, is set to make waves in the healthcare sector. On February 27, 2025, its Chief Executive Officer Bryan Kobel will be addressing the Cancer Progress Panel at the 18th Annual European Life Sciences CEO Forum. The event will take place at the Hilton Zurich Airport Hotel, spanning from February 26 to 27, and is expected to focus heavily on pioneering HealthTech topics, which include artificial intelligence, diagnostic innovations, and market convergence.

The forum promises to be an enriching experience, gathering thought leaders from various sectors within the life sciences. Not only will Kobel participate in discussions surrounding cancer therapies, but he will also engage with high-level keynotes and panel discussions scheduled throughout the event, totaling over 12 hours of knowledge sharing. Among the diverse range of topics, the forum will feature presentations by over 50 public, private, and emerging companies eager to showcase their innovative solutions to potential investors and partners.

TC BioPharm stands at the forefront of developing allogeneic gamma-delta T cell therapies, particularly focusing on cancer treatment. With ongoing pivotal clinical trials that showcase the significant potential of these therapies, the company aims to transform the landscape of cancer treatment. Kobel's participation in the upcoming panel serves as a testament to this mission. He is dedicated to showcasing the efficacy of gamma-delta T cells, which play a crucial role in the immune response against cancerous cells.

According to the company, these naturally occurring immune cells channel both innate and adaptive immunity, creating a robust framework for distinguishing between healthy and diseased tissue. TC BioPharm has taken an innovative approach by introducing its proprietary CryoTC technology, which allows for providing frozen gamma-delta T cell treatments to clinics globally. This strategic development is key to ensuring consistent and effective therapy delivery in various clinical settings.

Through rigorous research and collaboration, TC BioPharm aspires to lead the charge against some of the most challenging forms of cancer, including acute myeloid leukemia, where initial human efficacy data have already shown promising results. The upcoming European Life Sciences CEO Forum is a strategic opportunity for Kobel not only to highlight the ongoing advancements in cancer therapy but also to discuss potential collaborations that could accelerate the development of transformative treatments in the field.

Looking ahead, TC BioPharm remains committed to their mission of advancing human health through innovative biopharmaceutical developments. The company's dedication to research, clinical trials, and bringing new therapies to market underlines their leadership in the biotechnology landscape.

As Kohbel prepares for this important discussion at the forum, industry stakeholders and investors alike are keen to see how this dialogue will shape the future of cancer treatment and healthcare innovations. For more information about this noteworthy event and TC BioPharm’s contributions to the pharmaceutical sector, interested parties can visit the company's website or consult the forum agenda for further details on the panel discussions.

This forecast includes forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. All expressions indicating expectations and beliefs are inherently risky and should be regarded with caution. Investors can find further details regarding the company's operational risks in prior SEC filings, which are accessible on the company's investor relations page and the SEC website.